Pooled evidence suggested that topical anaesthetic creams ( TAs ) , tramadol , selective serotonin reuptake inhibitors ( SSRIs ) , and phosphodiesterase type 5 inhibitors ( PDE5is ) are more effective at prolonging IELT comparing with placebo .
Conclusions We recommend the initial use of dapoxetine 30 mg OD for PE because it has been tested in largest and better design ed clinical trials rather than it is more effective than the other drugs studied .
TAs and tramadol 50 mg OD can be used as a viable alternative to oral treatment with SSRIs .
PDE5is combined with SSRIs are more effective than SSRIs monotherapy but are also associated with more side effects .
Purpose The purpose of the study was to conduct a systematic evaluation of the different general prescribed drugs for  premature ejaculation ( PE ) .
Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study.
PURPOSE The efficacy of sertraline hydrochloride for the treatment of  premature ejaculation  is evaluated . MATERIAL S AND METHODS A total of 37 potent men , 19 to 70 years old ( mean age 41 ) , with premature ejaculation were treated with 50 mg . oral sertraline and placebo in a controlled r and omized single-blind crossover trial . All men were either married or in a stable relationship . None of the patients received any formal psychosexual therapy . Chronic open label treatment with sertraline was continued in 29 patients who had achieved an increase in ejaculatory latency times over pretreatment levels with active drug in the initial crossover study . In an attempt to identify which patients could maintain the improved ejaculatory control after withdrawal of the active drug , serial drug withdrawal was conducted every 4 weeks with drug initiation after a further 2 weeks if improved ejaculatory control was not maintained . RESULTS The mean pretreatment ejaculatory latency time was 0.3 minute ( range 0 to 1 ) . The mean ejaculatory interval after 4 weeks of treatment was 3.2 minutes ( range 1 minute to anejaculation ) with sertraline and 0.5 minute ( range 0 to 1 ) with placebo ( p < 0.001 ) . Intravaginal ejaculation was achieved for the first time in 5 patients with primary premature ejaculation and 2 patients experienced anejaculation . One patient described minor drowsiness and anorexia , and 2 patients described mild , transient gastrointestinal upset . Staged drug withdrawal allowed 20 of the 29 patients ( 67 % ) on chronic open label treatment with sertraline to discontinue the drug after a mean interval of 7.3 months with a mean ejaculatory latency time of 4.1 minutes ( range 1 to 12 ) . CONCLUSIONS Sertraline appears to be a useful agent in the pharmacological treatment of premature ejaculation
Pooled evidence suggested that topical anaesthetic creams ( TAs ) , tramadol , selective serotonin reuptake inhibitors ( SSRIs ) , and phosphodiesterase type 5 inhibitors ( PDE5is ) are more effective at prolonging IELT comparing with placebo .
Conclusions We recommend the initial use of dapoxetine 30 mg OD for PE because it has been tested in largest and better design ed clinical trials rather than it is more effective than the other drugs studied .
TAs and tramadol 50 mg OD can be used as a viable alternative to oral treatment with SSRIs .
PDE5is combined with SSRIs are more effective than SSRIs monotherapy but are also associated with more side effects .
Purpose The purpose of the study was to conduct a systematic evaluation of the different general prescribed drugs for  premature ejaculation ( PE ) .